For generations, people have suffered from brain cancers, neurodegenerative diseases, and metabolic disorders, and most drugs haven’t been optimized to deliver the right amount of dosage to the brain. One reason for that is the blood-brain barrier. That’s why in this episode, we take a look at Bioasis Technologies (TSX.V: BTI) (OTCQB: BIOAF). Their proprietary brain delivery technology, the xB3³ platform, transports medicine across the blood-brain barrier to offer a more successful treatment for diseases of the central nervous system. We take a look at their tech, their stock price and financials. Tune in!
Bioasis Technologies (BTI.V): To Invest or Not?
Latest Articles
- Standard Uranium (STND.V): Now a triple threat as Sprott goes nuclear on uranium buy
- Zefiro Methane Corp (ZEFI.CBOE): Caps orphaned oil wells, cleans the environment, and makes money
- Victory lap: Five companies we told you about and how far up they’ve gone since
- Standard Uranium (STND.V) coverage sees stock rise 90% in three days
- The promo engine is revving on Magma Silver (MGMA.V)
Top Searches
Abitibi Greenstone Belt Barrick Gold best canadian cannabis company biotech Bitcoin blockchain bullion Canada cannabis CBD China Chris Parry covid cryptocurrency DEFN.V Fraser Institute gambling Gold gold price. gold prices Greg Nolan hemp inflation interest rates investing investments lithium Lukas Kane marijuana mining money Newmont Goldcorp Nexus Gold pharmaceuticals psychedelics resources shrooms stock market stocks technology trading uranium wealth wealth creation weed
by
Leave a Reply